During the "14th Five-Year Plan" period, the national drug sampling pass rate has remained stable at over 99.4%.

During the "14th Five-Year Plan" period, China comprehensively deepened the reform of drug and medical device regulation, promoted the high-quality development of the pharmaceutical industry, and maintained the national drug sampling pass rate at above 99.4%. Yang Sheng, deputy director of the National Medical Products Administration, stated that they support enterprises in conducting clinical trials of drugs globally, in order to shorten the global market entry cycle for drugs. They also support foreign-invested enterprises in introducing original drugs, biologics, and high-end medical equipment for domestic production. They are expanding the scope of export certification for drugs and medical devices, providing strong support for Chinese drugs to "go global". They are accelerating the establishment of three sub-centers in the Beijing-Tianjin-Hebei, Central China, and Southwest regions. They are implementing a scientific action plan for drug regulation, accelerating the development of new tools, standards, and methods for regulation.